insights_auto
Outlook: 31.2% bullish·6.2% bearish
Go to analysischevron_right
AMGN:NASDAQ
Amgen Inc
$421.51
arrow_downward
-0.50%(-2.13) 1D
$416.71
arrow_downward
-1.14% (-4.80)todayPre-market
Closed: Sep 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMGN...
Open
$424.01
High
$426.59
Low
$420.63
Mkt. cap
227.88B
Avg. vol.
2.89M
Volume
4.57K
Dividend
2.39%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
26.18
52-wk high
$447.01
52-wk low
$283.00
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
Open
$424.01
High
$426.59
Low
$420.63
Mkt. cap
227.88B
Avg. vol.
2.89M
Volume
4.57K
Dividend
2.39%
Quarterly dividend
$2.52
Ex-dividend date
Aug 21, 2026
P/E ratio
26.18
52-wk high
$447.01
52-wk low
$283.00
EPS
$16.10
Beta
0.43
Shares outstanding
540.63M
No. of employees
32K
News stories
From web sources and news partners
Simply Wall St
·
19 hours ago
Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?
AD HOC NEWS
·
1 day ago
Amgen stock trades at EUR 372.83 after mixed analyst calls
News Corp
·
1 day ago
Amgen Inc. stock outperforms competitors on strong trading day
Yahoo Finance
·
2 days ago
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
Profile
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
About Amgen Inc
CEORobert A. Bradway
Employees31.5K
Founded1980
HeadquartersThousand Oaks, California, United States
SectorBiotechnology
Websiteamgen.com